<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4902">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01957202</url>
  </required_header>
  <id_info>
    <org_study_id>200286</org_study_id>
    <nct_id>NCT01957202</nct_id>
  </id_info>
  <brief_title>A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, 3 Way, Incomplete Block Cross Over Study in Subjects With Allergic Rhinitis to Assess the Effect of Once Daily Single and Repeat Doses of Intranasal Fluticasone Furoate/Levocabastine Fixed Dose Combination (FDC) Relative to Levocabastine and Fluticasone Furoate Alone on the Onset and Magnitude of Symptoms of Rhinitis in an Allergen Challenge Chamber</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a randomised, double blind, placebo controlled, 3-way, incomplete block
      crossover study to evaluate the effect of single and repeat doses of levocabastine, FF,
      placebo and a FDC of FF/levocabastine administration in AR subjects. The total expected
      study duration for each individual participating in the study will be a maximum of up to 20
      weeks (including the screening and follow-up). This will be a three period study and
      subjects will be assigned to a sequence of three treatments. There will be a wash-out period
      of 14-28 days between two treatment periods. The rational for this study is to demonstrate
      proof of concept with the FDC of FF and levocabastine compared with each of the components
      administered alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Total Nasal Symptom Score (TNSS) after repeat   FF/levocabastine compared to repeat FF alone</measure>
    <time_frame>Day 8 of each treatment period (Upto 80 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>TNSS will be assessed on 4 components: nasal congestion, rhinorrhea, nasal itch and sneeze, on a 4-point scale of 0-3 for maximum TNSS of 12, after 8-day repeat   FF/levocabastine compared to 8-day repeat FF alone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TNSS after repeat FF/levocabastine compared to repeat levocabastine alone</measure>
    <time_frame>Day 8 of each treatment period (Upto 80 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>TNSS will be assessed on 4 components: nasal congestion, rhinorrhea, nasal itch and sneeze, on a 4-point scale of 0-3 for maximum TNSS of 12, after 8-day repeat   FF/levocabastine compared to 8-day repeat levocabastine alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TNSS and Total Ocular Symptom Score (TOSS) after single dose of FF/levocabastine compared to FF alone</measure>
    <time_frame>Day 8 of each treatment period (Upto 80 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The onset and magnitude of symptom relief on TNSS and TOSS will assessed following single dose of FF/levocabastine compared to FF alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNSS and TOSS after single dose of FF/levocabastine compared to levocabastine alone</measure>
    <time_frame>Day 8 of each treatment period (Upto 80 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The onset and magnitude of symptom relief on TNSS and TOSS will assessed following single dose of FF/levocabastine compared to levocabastine alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TOSS after repeat FF/levocabastine compared to repeat FF alone</measure>
    <time_frame>Day 8 of each treatment period (Upto 80 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>TOSS will be assessed on components: Red, Itchy, and Tearing Eyes, on a 4-point scale of 0-3 for maximum TOSS of 9, average of two eyes, after 8-day repeat   FF/levocabastine compared to 8-day repeat FF alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TOSS after repeat FF/levocabastine compared to repeat levocabastine alone</measure>
    <time_frame>Day 8 of each treatment period (Upto 80 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>TOSS will be assessed on components: Red, Itchy, and Tearing Eyes, on a 4-point scale of 0-3 for maximum TOSS of 9, average of two eyes, after 8-day repeat   FF/levocabastine compared to 8-day repeat levocabastine alone</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Rhinitis, Allergic, Perennial and Seasonal</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each Subject will be assigned to a sequence of three treatments (e.g ABC, BCD, ACD): A=Two, 50 microliter (mcqL) sprays per nostril of FF, total dose 100 microgram (mcg); B=Two, 50 mcqL sprays per nostril of levocabastine, total dose 200 mcg; C=Two, 50 mcql sprays per nostril of FF/levocabastine FDC, total daily dose 100 mcg FF and 200 mcg levocabastine; D=Two, 50 mcql sprays per nostril of placebo. There will be a wash out period of 14-28 days between two treatment periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF/levocabastine</intervention_name>
    <description>FF/levocabastine (25mcg/50 mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF</intervention_name>
    <description>FF (25mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levocabastine</intervention_name>
    <description>levocabastine (50mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of AR, as determined by the presence of rhinitis symptoms that last for
             several months per year, for more than 1 year and are not attributed to infections or
             nasal abnormalities.

          -  Subjects have a TNSS score of &gt;=6 during the screening allergen challenge chamber.

          -  Subjects have a positive skin prick test (wheal &gt;=4 millimeter [mm]) for seasonal
             pollen at or within the 12 months preceding the screening visit.

          -  Subjects have a positive radioallergosorbent test (RAST) (&gt;=class 2) for seasonal
             pollen at or within the 12 months preceding the screening visit.

          -  There are no conditions or factors that would make the subject unlikely to be able to
             stay in the chamber for 5 hours.

          -  Male/females between 18 and 65 years of age inclusive, at the time of signing the
             informed consent.

          -  Healthy as determined by a responsible and experienced physician, based on a medical
             evaluation including medical history, physical examination and laboratory tests.  A
             subject with a clinical abnormality or laboratory parameter(s) which is/are not
             specifically listed in the inclusion or exclusion criteria, outside the reference
             range for the population being studied may be included only if the Investigator agree
             and document that the finding is unlikely to introduce additional risk factors and
             will not interfere with the study procedures.

          -  Body weight &gt;=50 kg and body mass index (BMI) within the range 19-30 kilogram per
             meter suare (kg/m^2) (inclusive).

          -  A female subject is eligible to participate if she is of:

        Non-childbearing potential defined as pre-menopausal females with a documented tubal
        ligation or hysterectomy [for this definition, &quot;documented&quot; refers to the outcome of the
        investigator's/designee's review of the subject's medical history for study eligibility,
        as obtained via a verbal interview with the subject or from the subject's medical
        records]; or postmenopausal defined as 12 months of spontaneous amenorrhea (in
        questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] &gt;40
        milli international unit per milliliter (MIU/milliliter [mL]) and estradiol &lt;40 picogram
        per milliliter[pg/mL] (&lt;147 picomole per liter [pmol/L]) is confirmatory).

        Child-bearing potential with negative pregnancy test as determined by urine beta-human
        chorionic gonadotropin (Î²-hCG) test at screening or prior to dosing and;

          -  Agrees to use one of the contraception methods for an appropriate period of time (as
             determined by the product label or investigator) prior to the start of dosing to
             sufficiently minimize the risk of pregnancy at that point.  Female subjects must
             agree to use contraception until 1 week post-last dose

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  Subjects should be non-smokers, which for this study is defined as having smoked &lt;10
             packs per year in their lifetime, and have not smoked in the 6 months prior to the
             screening visit.

          -  alanine aminotransferase (ALT), alkaline phosphatase and bilirubin &lt;=1.5x upper limit
             of normal (ULN) (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is
             fractionated and direct bilirubin &lt;35%).

          -  Based on single or averaged corrected QT interval (QTc) values of triplicate
             electrocardiogram (ECGs) obtained over a brief recording period: Fridericia's QTC
             (QTcF) &lt;450 milliseconds (msec).

        Exclusion Criteria:

          -  Nasal abnormalities likely to affect the outcome of the study, that is nasal septal
             perforation, nasal polyps, sinusitis other nasal malformations.

          -  History of frequent nose bleeds

          -  Patients with rhinitis medicamentosa

          -  Current or chronic history of liver disease, or known hepatic or biliary
             abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  Significant renal impairment, which based on the opinion of the investigator, would
             preclude the subjects participation in the study.

          -  History of regular alcohol consumption within 6 months of the study defined as:

          -  An average weekly intake of &gt;21 units for males or &gt;14 units for females.  One unit
             is equivalent to 8 gram of alcohol: a half-pint (~240 mL) of beer, 1 glass (125 mL)
             of wine or 1 (25 mL) measure of spirits.

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or GSK
             Medical Monitor, contraindicates their participation.

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of screening

          -  A positive pre-study drug/alcohol screen.

          -  A positive test for human immunodeficiency virus (HIV) antibody.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1150</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 27, 2014</lastchanged_date>
  <firstreceived_date>October 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>levocabastine fixed dose combination, Rhinitis, Allergic, Perennial and Seasonal, Allergic Rhinitis, fluticasone furoate</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Levocabastine</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
